ATE192651T1 - Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung - Google Patents

Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung

Info

Publication number
ATE192651T1
ATE192651T1 AT90914807T AT90914807T ATE192651T1 AT E192651 T1 ATE192651 T1 AT E192651T1 AT 90914807 T AT90914807 T AT 90914807T AT 90914807 T AT90914807 T AT 90914807T AT E192651 T1 ATE192651 T1 AT E192651T1
Authority
AT
Austria
Prior art keywords
production
cell
protective
treatment
disclosed
Prior art date
Application number
AT90914807T
Other languages
English (en)
Inventor
Raymond A Daynes
Barbara A Araneo
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE192651T1 publication Critical patent/ATE192651T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90914807T 1989-09-25 1990-09-25 Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung ATE192651T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41227089A 1989-09-25 1989-09-25
PCT/US1990/005452 WO1991004030A1 (en) 1989-09-25 1990-09-25 Use of steroid hormones in compositions for inducing t cell lymphokine production

Publications (1)

Publication Number Publication Date
ATE192651T1 true ATE192651T1 (de) 2000-05-15

Family

ID=23632331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914807T ATE192651T1 (de) 1989-09-25 1990-09-25 Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung

Country Status (9)

Country Link
US (2) US5540919A (de)
EP (1) EP0494224B1 (de)
JP (1) JP2505313B2 (de)
AT (1) ATE192651T1 (de)
AU (2) AU652130B2 (de)
CA (1) CA2066716A1 (de)
DE (1) DE69033541D1 (de)
DK (1) DK0494224T3 (de)
WO (1) WO1991004030A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5824313A (en) * 1989-09-25 1998-10-20 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5753237A (en) * 1989-09-25 1998-05-19 University Of Utah Research Foundation Method for augmenting immunological responses
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5641766A (en) * 1990-08-29 1997-06-24 Humanetics Corporation UP-regulation of immune system with Δ 5-Androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
JPH07504198A (ja) * 1992-02-24 1995-05-11 イースト カロライナ ユニバーシティ デヒドロエピアンドロステロンおよびその類縁体を用いる処置によって発癌を抑制する方法
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
US5736537A (en) * 1995-09-12 1998-04-07 Estee Lauder, Inc. Dehydroep:androsterone sailcylate useful against skin atrophy
AU7468196A (en) * 1995-10-27 1997-05-15 Merck & Co., Inc. Conjugates of gonadotropin releasing hormone
GB9612990D0 (en) * 1996-06-20 1996-08-21 Stanford Rock Ltd Compositions and methods for the treatment of chronic infections
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
CA2333256A1 (en) 1998-05-29 1999-12-02 Bone Care International, Inc. Method for making hydroxy-25-ene-vitamin d compounds
US7229621B2 (en) * 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20080015174A1 (en) * 1998-11-24 2008-01-17 Reading Christopher L Metabolic Disease Treatments
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
CA2386095A1 (en) 1999-09-30 2001-04-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US6359012B1 (en) 1999-12-22 2002-03-19 Bone Care International, Inc. Method for making 24(S)-hydroxyvitamin D2
US6670146B2 (en) 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
US20040138187A1 (en) 2002-08-28 2004-07-15 Reading Christopher L. Therapeutic treatment methods
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US20050014734A1 (en) * 2003-07-18 2005-01-20 Genovate Biotechnology Co., Ltd. Modulation of interleukin-10 by DHEA
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
WO2008046576A1 (en) * 2006-10-16 2008-04-24 Transgene S.A. Use of glucocorticoid antagonists in vaccination
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004003A (en) * 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4080448A (en) * 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
US4110446A (en) * 1977-07-14 1978-08-29 Wisconsin Alumni Research Foundation Method of treating milk fever in dairy cattle with 1,25-dihydroxycholecalciferol
JPS55139320A (en) * 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
FR2494697A1 (fr) * 1980-11-21 1982-05-28 Roussel Uclaf Nouveaux derives steroides 3-amines, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant
US4661447A (en) * 1981-04-17 1987-04-28 Shanksville Corporation N.V. Regulatory glycoprotein for immune response and the use there of in the production of T-cell growth factor
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
DE3241113A1 (de) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen Vakzinen mit zuschlagstoffen
US4610978A (en) * 1983-03-22 1986-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
IE72193B1 (en) * 1983-08-02 1997-03-26 Res Corp Technologies Inc Steroids useful as anti-cancer anti-obesity anti-hyperglycemic anti-autoimmune and anti-hypercholesterolemic agents
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4666898A (en) * 1983-12-28 1987-05-19 Jackson Lab. Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
EP0230574A3 (de) * 1986-01-31 1989-03-22 Yale University Pharmazeutische Zusammensetzungen gegen durch LAV/HTLV-III-Virus verursachte Infektionen und ihre Verwendung
US4778750A (en) * 1986-02-19 1988-10-18 Imreg, Inc. Diagnostic methods for immune function
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
DE3862405D1 (de) * 1987-03-09 1991-05-23 Alza Corp Zusammensetzung zur vorbeugung einer kontaktallergie durch gleichzeitiges verabreichen eines kortikosteroids mit einem sensiblisierenden arzneistoff.
US5000956A (en) * 1987-03-09 1991-03-19 Alza Corporation Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites

Also Published As

Publication number Publication date
DE69033541D1 (de) 2000-06-15
EP0494224A1 (de) 1992-07-15
AU652130B2 (en) 1994-08-18
JPH05502856A (ja) 1993-05-20
US5540919A (en) 1996-07-30
AU6501990A (en) 1991-04-18
CA2066716A1 (en) 1991-03-26
DK0494224T3 (da) 2000-08-07
EP0494224B1 (de) 2000-05-10
JP2505313B2 (ja) 1996-06-05
EP0494224A4 (en) 1992-10-14
WO1991004030A1 (en) 1991-04-04
US5827841A (en) 1998-10-27
AU7572794A (en) 1994-12-08
AU667018B2 (en) 1996-02-29

Similar Documents

Publication Publication Date Title
ATE192651T1 (de) Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung
Collins et al. Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro.
Thivolet et al. Long-term survival and immunological tolerance of human epidermal allografts produced in culture
ES2053758T3 (es) Una nueva molecula polipeptidica.
EP0656788A4 (de) Hla bindepeptide und seine verwendungen
ATE142691T1 (de) Proteine mit faktor-viii-aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende pharmazeutische zusammensetzungen
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
ATE76905T1 (de) Reinigung von rekombinanten interleukin-2.
BG49827A3 (bg) Метод за получаване на пречистен биологично активен рекомбинантен човешки колоний стимулиращ фактор
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
SE8701934D0 (sv) Enhanced expression of human interleukin-2 in mammalian cells
Bragg et al. Protein synthesis in mouse spermatozoa
UA6028A1 (uk) Спосіб одержання біологічно активної композиції
Barker et al. Gamma‐interferon induced human keratinocyte HLA‐DR synthesis: the role of dermal activated T lymphocytes
DE3855634D1 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
NO873437D0 (no) Human placenta angiogen faktor i stand til aa stimulere kapillaer endotelcelle-proteasesyntese, dna-syntese og migrasjon.
Grencis et al. Lymphokine production by T cells generated during infection with Trichinella spiralis
DK0765398T3 (da) Population af celler, der er beriget for myeloide og/eller lymfoide progenitorer og fremgangsmåde til fremstilling og anvendelse deraf
Lancaster et al. Isolation of a purified skin test antigen from Blastomyces dermatitidis yeast-phase cell wall
SE8303925D0 (sv) Interferon e
Klapper Jr et al. Inhibition of peptic digestion of serum albumin by fatty acids
HUP9800520A2 (hu) Génexpresszió emlős sejtekben
Mizobe et al. Induction of a specific protein by oestradiol in rat pineals in culture
ROBBOY et al. Zone electrophoresis and prolactin activity of rat adenohypophysis cultivated in vitro
Lindahl-Kiessling et al. A factor in amniotic fluid inhibiting phytohemagglutinin (PHA) induced lymphocyte growth

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties